Oruka Therapeutics (ORKA) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is ORKA's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Oruka Therapeutics, Inc. (ORKA) Presents at UBS Global Biopharma Conference 2026 Transcript…

EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A…

Candriam S.C.A. trimmed its holdings in Oruka Therapeutics, Inc. (NASDAQ: ORKA) by 3.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional inv…

MENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment …

Oruka Therapeutics NASDAQ: ORKA reported interim week 16 results from EVERLAST-B, a Phase IIb dose-ranging study of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The company said its 600-milligram regimen …

Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript…

Oruka Therapeutics Inc. (NASDAQ:ORKA) on Monday reported positive Week 16 results from its EVERLAST-B Phase 2b clinical trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis.…

61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class ORKA-001 on track to advance into…

MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment …

Oruka Therapeutics (NASDAQ: ORKA - Get Free Report)'s stock had its "buy" rating restated by analysts at BTIG Research in a research report issued on Monday, Benzinga reports. They currently have a $151.00 price target o…

Oruka Therapeutics is positioned as a leader in ultra-long-acting injectable treatments for psoriasis, with ORKA-001 showing class-leading efficacy. ORKA-001's PASI 100 and PASI 90 rates at Week 28 reinforce its durabili…

Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.…

Oruka Therapeutics Inc. (NASDAQ:ORKA) on Wednesday reported positive week 28 outcomes from its Phase 2a clinical trial evaluating ORKA-001 for moderate-to-severe plaque psoriasis.…

PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001 ORKA-001 maintained …

MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment…

Oruka's three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead.…

BlackRock Inc. purchased a new position in Oruka Therapeutics, Inc. (NASDAQ: ORKA) during a recent quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fu…

MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment …
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

